Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids.

Shirure VS, Bi Y, Curtis MB, Lezia A, Goedegebuure MM, Goedegebuure SP, Aft R, Fields RC, George SC.

Lab Chip. 2018 Dec 7;18(23):3687-3702. doi: 10.1039/c8lc00596f. Epub 2018 Nov 5.

PMID:
30393802
2.

Recruitment of CCR2+ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer.

Grossman JG, Nywening TM, Belt BA, Panni RZ, Krasnick BA, DeNardo DG, Hawkins WG, Goedegebuure SP, Linehan DC, Fields RC.

Oncoimmunology. 2018 Aug 1;7(9):e1470729. doi: 10.1080/2162402X.2018.1470729. eCollection 2018.

PMID:
30228938
3.

Preclinical and clinical development of neoantigen vaccines.

Li L, Goedegebuure SP, Gillanders WE.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii11-xii17. doi: 10.1093/annonc/mdx681. Review.

PMID:
29253113
4.

Development of an adenovirus vector vaccine platform for targeting dendritic cells.

Sharma PK, Dmitriev IP, Kashentseva EA, Raes G, Li L, Kim SW, Lu ZH, Arbeit JM, Fleming TP, Kaliberov SA, Goedegebuure SP, Curiel DT, Gillanders WE.

Cancer Gene Ther. 2018 Feb;25(1-2):27-38. doi: 10.1038/s41417-017-0002-1. Epub 2017 Dec 15.

5.

Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity.

Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, Miller CA, Ellis MJ, Mardis ER, Hansen T, Fleming TP, Goedegebuure SP, Gillanders WE.

Cancer Immunol Res. 2017 Jul;5(7):516-523. doi: 10.1158/2326-6066.CIR-16-0264. Epub 2017 Jun 15.

6.

The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.

Hashim YM, Vangveravong S, Sankpal NV, Binder PS, Liu J, Goedegebuure SP, Mach RH, Spitzer D, Hawkins WG.

J Exp Clin Cancer Res. 2017 Jan 17;36(1):14. doi: 10.1186/s13046-016-0470-4.

7.

Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.

Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG.

Oncotarget. 2016 Jun 7;7(23):33529-41. doi: 10.18632/oncotarget.9551.

8.

Erratum: Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.

Tatzel K, Kuroki L, Dmitriev I, Kashentseva E, Curiel DT, Goedegebuure SP, Powell MA, Mutch DG, Hawkins WG, Spitzer D.

Sci Rep. 2016 May 4;6:25217. doi: 10.1038/srep25217. No abstract available.

9.

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC.

Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.

10.

Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.

Tatzel K, Kuroki L, Dmitriev I, Kashentseva E, Curiel DT, Goedegebuure SP, Powell MA, Mutch DG, Hawkins WG, Spitzer D.

Sci Rep. 2016 Mar 3;6:22661. doi: 10.1038/srep22661. Erratum in: Sci Rep. 2016 May 04;6:25217.

11.

Developing a clinical development paradigm for translation of a mammaglobin-A DNA vaccine.

Li L, Goedegebuure SP, Fleming TP, Gillanders WE.

Immunotherapy. 2015;7(7):709-11. doi: 10.2217/imt.15.40. Epub 2015 Aug 7. No abstract available.

12.

Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.

Wilkinson-Ryan I, Kim J, Kim S, Ak F, Dodson L, Colonna M, Powell M, Mutch D, Spitzer D, Hansen T, Goedegebuure SP, Curiel D, Hawkins W.

PLoS One. 2015 May 1;10(5):e0125851. doi: 10.1371/journal.pone.0125851. eCollection 2015.

13.

Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes.

Soysal SD, Muenst S, Kan-Mitchell J, Huarte E, Zhang X, Wilkinson-Ryan I, Fleming T, Tiriveedhi V, Mohanakumar T, Li L, Herndon J, Oertli D, Goedegebuure SP, Gillanders WE.

Breast Cancer Res Treat. 2014 Oct;147(3):527-37. doi: 10.1007/s10549-014-3129-x. Epub 2014 Sep 12.

14.

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG.

Cancer Res. 2014 Sep 15;74(18):5057-69. doi: 10.1158/0008-5472.CAN-13-3723. Epub 2014 Jul 31.

15.

Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer.

Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, Denardo DG, Goedegebuure SP, Linehan DC.

Cancer Immunol Immunother. 2014 May;63(5):513-28. doi: 10.1007/s00262-014-1527-x. Epub 2014 Mar 21.

16.

A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma.

Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC.

J Cancer Ther. 2013 May;4(3):797-803.

17.

Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.

Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC.

Clin Cancer Res. 2013 Jul 1;19(13):3404-15. doi: 10.1158/1078-0432.CCR-13-0525. Epub 2013 May 7.

18.

Leucoagglutinin induces differential proliferation of lymphocyte subsets.

Goedegebuure SP, van de Griend RJ, Ronteltap CP, Bolhuis RL.

Biotherapy. 1989;1(2):73-83.

PMID:
2577067
19.

Cloning of human CD3+ T cells and CD3- natural killer cells and requirements for long-term expansion.

van de Griend RJ, Goedegebuure SP, van Krimpen BA, Bolhuis RL.

Transplant Proc. 1988 Apr;20(2):149-54. No abstract available.

PMID:
2966464

Supplemental Content

Loading ...
Support Center